Company Overview
NeOnc Technologies Holdings, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of therapeutic treatments specifically targeting intracranial malignancies. The company functions within the broader healthcare sector and the specialized biotechnology industry, positioning itself to leverage advancements in molecular biology for oncology applications. In terms of scale, the entity holds a market capitalization of $173.51M and reports annual revenue of $59,990 over the trailing twelve-month period, while its employee count is currently unlisted in available records. The market capitalization figure of $173.51M indicates that the market values the company's pipeline assets and intellectual property at a level significantly higher than its current revenue generation, which is typical for clinical-stage biotechnology firms where future potential outweighs present profitability. The revenue figure of $59,990 suggests the company is in a pre-commercialization or very early commercialization phase, relying heavily on capital markets and asset sales rather than established product sales to sustain operations.
Financial Health
The company reported a revenue of $59,990 for the trailing twelve months, yet it generated a net income of $-48,875,088, revealing a substantial gap between top-line activity and bottom-line profitability that points to a heavy cost structure driven by clinical trial expenses and research and development investments. Despite the significant net loss, the company maintains positive free cash flow of $785,115, which provides a degree of financial flexibility by generating cash from operations even while burning through cash reserves for growth initiatives. The margin analysis shows a gross margin of 100.0%, indicating that the cost of goods sold is negligible relative to revenue, which is standard for early-stage biotechnology companies, contrasted sharply by an operating margin of -77706.3% and a profit margin of 0.0%, both of which highlight the intense operational leverage and high fixed costs inherent in the clinical development phase. Regarding liquidity and leverage, the company holds $1.51M in cash against $5.08M in debt, while a debt-to-equity ratio is not available, suggesting the balance sheet is currently leveraged and dependent on equity financing or asset monetization to service obligations. The current ratio stands at 0.19, a figure that indicates the company faces significant short-term liquidity constraints as current liabilities exceed current assets. Furthermore, the return on equity is not available and the return on assets is -853.6%, metrics that collectively reveal that management is currently unable to generate returns on the capital invested in the business, a common characteristic of companies in the deep clinical stage of development.
Valuation Assessment
The valuation metrics present a complex picture with a trailing P/E ratio of N/A and a forward P/E of -4.78, implying that the market is not valuing the stock based on historical earnings but is instead projecting a future trajectory where earnings may turn positive, though the negative forward P/E suggests analysts anticipate continued losses or that earnings are negative in the projected period. The price-to-book ratio is reported at -11.66, a negative figure that indicates the market value of the company is substantially below its book value, often reflecting the high risk associated with the clinical-stage nature of the business and the potential for the asset base to be impaired if clinical trials fail. Alternative valuation metrics such as the price-to-sales ratio of 2892.39 and an EV/EBITDA of N/A suggest that investors are pricing the stock almost entirely on the potential of the pipeline rather than current sales or earnings power, as the extremely high price-to-sales multiple reflects the premium placed on the lead product candidates in Phase IIa clinical trials. The stock has exhibited significant volatility with a 52-week high of $25.00 and a 52-week low of $3.20, meaning the current trading price sits in a wide range relative to its recent performance history, though the specific current price is not listed to calculate the exact percentage distance from the high. The beta value is not available, which prevents a direct comparison of the stock's price volatility relative to the broader market index, but the wide swing between the 52-week high and low implies that the asset class carries inherent high volatility typical of small-cap biotechnology equities.
Growth & Income
The available data indicates that revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, meaning there is no historical comparative data to determine whether earnings are growing faster or slower than revenue, as the company lacks the consistent revenue history required to calculate these growth rates. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company reinvests all available capital and earnings back into the development of NEO100 and NEO212 rather than distributing income to shareholders. The absence of a dividend policy combined with the negative earnings profile confirms that the company's overall growth and income profile is entirely dependent on successful clinical trial outcomes and potential future commercialization rather than current cash distributions.